Plosker, Greg L.; Keam, Susan J. - In: Disease Management and Health Outcomes 15 (2007) 1, pp. 57-63
The addition of candesartan cilexetil (Atacand(R), Amias(R), Blopress(R), Kenzen(R), Ratacand(R)) to standard therapy for chronic heart failure (CHF) provided important clinical benefits at little or no additional cost in France, Germany, and the UK, according to a detailed economic analysis...